Hanmi Pharm to Fully Implement AI in QA, Pushing for Automated Quality Documentation
Selected for the Ministry of Science and ICT's AX Voucher Project
Automated APQR Drafting System to Launch Next Year
Expansion Planned Organization-wide, Including QC, R&D, and RA
Hanmi Pharm is set to fully automate its quality documentation work by deploying artificial intelligence (AI) across its "QA (Quality Assurance)" sector.
On September 7, Hanmi Pharm announced that it has been selected as the final recipient in the pharmaceutical and biotechnology sector for the "AX (AI Transformation) One-Stop Voucher Support Project," led by the Ministry of Science and ICT. The company will now proceed with the introduction and validation of AI solutions.
On the 28th of last month, key representatives from Hanmi Pharm, Samsung SDS, Megazone Cloud, and SelectStar took a commemorative photo after the launch ceremony of the "AX One-Stop Voucher Support Project" at Hanmi C&C Square in Songpa-gu, Seoul. Hanmi Pharm
View original imageThis project will be conducted as a consortium exclusively built on domestic infrastructure, aligning with the purpose of government support. Hanmi Pharm, which oversees the project, will lead the development of internal Standard Operating Procedures (SOPs), quality documents, IT governance, information security, and integration with the backbone systems. Samsung SDS is responsible for building the AX infrastructure, Megazone Cloud will handle the implementation and fine-tuning of AI solutions, and Selectstar will conduct validation as a third-party by building datasets and evaluating AI reliability.
Through the "Hanmi Q-Agent" project, Hanmi Pharm intends to leap forward as a global-level smart lab by fully implementing AI in its QA function. The project began in July and will run over two years, until December of next year.
Hanmi Pharm is launching an advanced QA initiative at its Pyeongtaek bio plant, which will serve as the forward base for the two-year program. In the first year, the AI will be trained on approximately 4,000 types of SOPs at the Pyeongtaek site, enabling it to provide evidence-based, accurate answers. In the second year, the system will be expanded to automatically draft annual product quality review (APQR) reports by section, using the data accumulated through training.
The key focus of this project is to develop a proprietary language model specifically tailored to Hanmi Pharm by fine-tuning Upstage’s "Solar" model, rather than relying on generic AI. This customized model will be used exclusively for advancing Hanmi Pharm’s internal quality processes and for quality assurance work related to innovative new drugs.
Through this initiative, Hanmi Pharm aims to transition its predominantly manual quality documentation work into an AI-driven collaboration process, thereby reducing the manpower required and enabling employees to focus on high-value tasks such as new drug development and global business. The company also plans to expand the model’s deployment beyond QA to encompass quality control (QC), research and development (R&D), regulatory affairs (RA), and pharmacovigilance (PV) across the organization. Additionally, the use of the model will be extended throughout the entire Hanmi Group, including Hanmi Science, Hanmi Fine Chemical, and Beijing Hanmi Pharm.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hanmi Pharm CEO Hwang Sangyeon stated, "In the pharmaceutical and biotechnology industries, the QA sector, which handles massive volumes of quality documents, has long faced limitations due to thorough manual work and a focus on post-response. Through this project in collaboration with specialized companies, we aim not only to support the quality assurance work for 'Ephe' ahead of its planned release in the second half of the year, but also to promote the successful rollout of an AI-driven innovation model throughout the group, starting with Pyeongtaek, further bolstering the global export competitiveness of Korean pharmaceuticals."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.